Nuveen LLC Takes Position in Simulations Plus, Inc. $SLP

Nuveen LLC acquired a new stake in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund acquired 47,067 shares of the technology company's stock, valued at approximately $1,154,000. Nuveen LLC owned approximately 0.23% of Simulations Plus at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of SLP. Barclays PLC boosted its holdings in shares of Simulations Plus by 2.7% in the fourth quarter. Barclays PLC now owns 29,229 shares of the technology company's stock worth $815,000 after acquiring an additional 756 shares during the period. First Trust Advisors LP boosted its stake in Simulations Plus by 47.3% in the 4th quarter. First Trust Advisors LP now owns 9,393 shares of the technology company's stock worth $262,000 after purchasing an additional 3,015 shares during the period. Dimensional Fund Advisors LP boosted its stake in Simulations Plus by 6.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 419,241 shares of the technology company's stock worth $11,693,000 after purchasing an additional 24,266 shares during the period. Tower Research Capital LLC TRC grew its holdings in Simulations Plus by 42.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company's stock valued at $72,000 after buying an additional 764 shares in the last quarter. Finally, State of Tennessee Department of Treasury increased its position in shares of Simulations Plus by 21.0% during the fourth quarter. State of Tennessee Department of Treasury now owns 11,813 shares of the technology company's stock valued at $329,000 after buying an additional 2,052 shares during the period. Institutional investors own 78.08% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on SLP shares. KeyCorp lowered shares of Simulations Plus from an "overweight" rating to a "sector weight" rating in a research report on Tuesday, July 15th. Zacks Research raised shares of Simulations Plus to a "hold" rating in a report on Tuesday, August 12th. Stephens decreased their price target on shares of Simulations Plus from $28.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, July 15th. William Blair reiterated an "outperform" rating on shares of Simulations Plus in a research report on Tuesday, July 15th. Finally, Craig Hallum dropped their price objective on Simulations Plus from $45.00 to $36.00 and set a "buy" rating for the company in a research note on Friday, June 13th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, Simulations Plus presently has an average rating of "Moderate Buy" and an average target price of $26.50.

Simulations Plus Trading Down 1.8%

Shares of Simulations Plus stock traded down $0.26 on Thursday, hitting $14.12. 260,049 shares of the company traded hands, compared to its average volume of 428,768. Simulations Plus, Inc. has a 12-month low of $12.39 and a 12-month high of $37.67. The company has a market cap of $284.24 million, a P/E ratio of -4.48 and a beta of 0.85. The firm's 50-day simple moving average is $14.67 and its 200 day simple moving average is $23.63.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its earnings results on Monday, July 14th. The technology company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.26 by $0.19. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%.The business had revenue of $20.36 million for the quarter, compared to analysts' expectations of $22.83 million. During the same quarter in the prior year, the firm earned $0.27 earnings per share. The firm's revenue was up 9.8% on a year-over-year basis. Analysts predict that Simulations Plus, Inc. will post 1.09 earnings per share for the current year.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.